Abstract: The present invention relates to a novel naphthyridinone derivative compound, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are each relevant to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.

Abstract: An organic light-emitting display device includes quantum dots and an RGB color filter layer having quantum dots and thus is capable of removing 100% of interference among red, green, and blue color filters.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues may be inhibited. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of fibronectin, CTGF2, ?-SMA, collagen 1A and the like during treatment of TGF-?. Therefore, the pharmaceutical composition according to the present invention may be effectively used in the prevention or treatment of fibrosis.

Abstract: The present invention relates to a mitochondrion containing a compound having the anticancer efficacy and uses thereof. It was confirmed that the mitochondrion efficiently deliver the compound to the tumor, and the anticancer effect of the mitochondrion containing the compound was confirmed. In particular, when an antibody or a fragment thereof that specifically binds to a tumor is bound to the surface of mitochondrion, the compound may be delivered specifically to the tumor. Therefore, the mitochondrion containing the compound according to the present invention may be effectively used for the treatment of cancer because the side effects of the compound are few.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-? which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.